

Bjorn Eliasson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8411321/bjorn-eliasson-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107
papers

4,557
citations

39
h-index

64
g-index

112
ext. papers

5,128
ext. citations

7
avg, IF

5.32
L-index

#	Paper	IF	Citations
107	One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. <i>Diabetes Care</i> , 2009 , 32, 762-8	14.6	327
106	Effects of exenatide on measures of β cell function after 3 years in metformin-treated patients with type 2 diabetes. <i>Diabetes Care</i> , 2011 , 34, 2041-7	14.6	194
105	The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. <i>Diabetes Care</i> , 2003 , 26, 1270-6	14.6	174
104	Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. <i>Diabetologia</i> , 2009 , 52, 65-73	10.3	170
103	Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. <i>BMJ Open</i> , 2012 , 2,	3	142
102	Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. <i>Diabetes Care</i> , 2008 , 31, 2038-43	14.6	119
101	New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). <i>Journal of Internal Medicine</i> , 2010 , 268, 471-82	10.8	116
100	Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 847-54	18.1	114
99	Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. <i>Diabetes Care</i> , 2010 , 33, 1734-7	14.6	110
98	The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003. <i>Diabetic Medicine</i> , 2005 , 22, 1420-6	3.5	103
97	One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. <i>Atherosclerosis</i> , 2010 , 212, 223-9	3.1	101
96	Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). <i>Diabetes Care</i> , 2010 , 33, 1640-6	14.6	100
95	Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes--data from the National Diabetes Register in Sweden. <i>Diabetes and Metabolism</i> , 2004 , 30, 261-8	5.4	91
94	Risk factors for the development of albuminuria and renal impairment in type 2 diabetes--the Swedish National Diabetes Register (NDR). <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 1236-43	4.3	90
93	Cigarette smoking and diabetes. <i>Progress in Cardiovascular Diseases</i> , 2003 , 45, 405-13	8.5	87
92	Effect of smoking reduction and cessation on cardiovascular risk factors. <i>Nicotine and Tobacco Research</i> , 2001 , 3, 249-55	4.9	83
91	Diabetes care--improvement through measurement. <i>Diabetes Research and Clinical Practice</i> , 2014 , 106 Suppl 2, S291-4	7.4	76

90	The size of large adipose cells is a predictor of insulin resistance in first-degree relatives of type 2 diabetic patients. <i>Obesity</i> , 2012 , 20, 932-8	8	74
89	Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. <i>Diabetes Care</i> , 2007 , 30, 496-502	14.6	73
88	Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. <i>Journal of Internal Medicine</i> , 2006 , 259, 314-22	10.8	71
87	Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. <i>Diabetologia</i> , 2012 , 55, 915-25	10.3	70
86	Adipocyte hypertrophy, inflammation and fibrosis characterize subcutaneous adipose tissue of healthy, non-obese subjects predisposed to type 2 diabetes. <i>PLoS ONE</i> , 2014 , 9, e105262	3.7	70
85	Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 374-7	6.7	68
84	Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. <i>Diabetes and Vascular Disease Research</i> , 2013 , 10, 520-9	3.3	61
83	Recent trends in life expectancy for people with type 1 diabetes in Sweden. <i>Diabetologia</i> , 2016 , 59, 1167-76	1.6	59
82	Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis. <i>Diabetologia</i> , 2010 , 53, 536-40	10.3	58
81	The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. <i>Diabetologia</i> , 2010 , 53, 1093-8	10.3	57
80	Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. <i>Thrombosis Research</i> , 2012 , 129, 32-5	8.2	54
79	Impaired phosphorylation and insulin-stimulated translocation to the plasma membrane of protein kinase B/Akt in adipocytes from Type II diabetic subjects. <i>Diabetologia</i> , 2000 , 43, 1107-15	10.3	53
78	Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register. <i>Diabetes Care</i> , 2011 , 34, 2095-100	14.6	52
77	The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. <i>PLoS ONE</i> , 2009 , 4, e4412	3.7	50
76	A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). <i>Diabetes Research and Clinical Practice</i> , 2011 , 93, 276-284	7.4	49
75	A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR). <i>Diabetic Medicine</i> , 2011 , 28, 1213-20	3.5	49
74	Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2015 , 38, 1518-27	14.6	47
73	Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). <i>Blood Pressure</i> , 2011 , 20, 348-54	1.7	46

72	Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2005 , 67, 258-66	7.4	45
71	Long-term prognosis in patients with type 1 and 2 diabetes mellitus after coronary artery bypass grafting. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1644-1652	15.1	44
70	Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP II). <i>Journal of Hypertension</i> , 2012 , 30, 2020-30	1.9	42
69	Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. <i>Journal of Human Hypertension</i> , 2003 , 17, 37-44	2.6	41
68	Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. <i>International Journal of Obesity</i> , 2007 , 31, 1140-7	5.5	39
67	Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden. <i>Diabetes Care</i> , 2014 , 37, 2974-81	14.6	37
66	The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). <i>Diabetes Research and Clinical Practice</i> , 2014 , 106, 136-44	7.4	37
65	Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. <i>Journal of Hypertension</i> , 2010 , 28, 2026-35	1.9	37
64	Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 diabetes: report from the Swedish National Diabetes Register. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 244-51	3.9	35
63	Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR). <i>Diabetes and Metabolism</i> , 2009 , 35, 439-46	5.4	34
62	Dust acoustic shock waves. <i>Physical Review E</i> , 2004 , 69, 067401	2.4	34
61	The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. <i>Primary Care Diabetes</i> , 2012 , 6, 53-9	2.4	31
60	Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. <i>Thrombosis Research</i> , 2007 , 120, 653-61	8.2	31
59	HbA1C and cancer risk in patients with type 2 diabetes--a nationwide population-based prospective cohort study in Sweden. <i>PLoS ONE</i> , 2012 , 7, e38784	3.7	30
58	The effect of alogliptin and pioglitazone combination therapy on various aspects of β cell function in patients with recent-onset type 2 diabetes. <i>European Journal of Endocrinology</i> , 2014 , 170, 565-74	6.5	29
57	Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. <i>Diabetes and Metabolism</i> , 2007 , 33, 269-76	5.4	29
56	Glycemic Control in Type 1 Diabetes and Long-Term Risk of Cardiovascular Events or Death After Coronary Artery Bypass Grafting. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 535-43	15.1	28
55	Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. <i>Diabetic Medicine</i> , 2005 , 22, 382-6	3.5	27

54	Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients. <i>Health and Quality of Life Outcomes</i> , 2015 , 13, 145	3	25
53	Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 506-12		25
52	Impact of ethnicity on progress of glycaemic control in 131,935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. <i>BMJ Open</i> , 2015 , 5, e007599	3	24
51	Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). <i>Diabetic Medicine</i> , 2009 , 26, 53-60	3.5	24
50	Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 97-105		24
49	Relationship between preoperative hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus. <i>International Journal of Cardiology</i> , 2016 , 202, 291-6	3.2	23
48	Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). <i>Diabetologia</i> , 2015 , 58, 2259-68	10.3	23
47	Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). <i>Diabetes Research and Clinical Practice</i> , 2009 , 86, 74-81	7.4	23
46	Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register. <i>PLoS ONE</i> , 2011 , 6, e18744	3.7	23
45	LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 1420-8	3.9	22
44	Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 717-26	6.7	22
43	Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment. <i>Diabetologia</i> , 2012 , 55, 2109-17	10.3	21
42	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study. <i>Diabetes Care</i> , 2020 , 43, 1326-1335	14.6	20
41	Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden. <i>International Journal of Environmental Research and Public Health</i> , 2014 , 11, 4939-52	4.6	19
40	Adipocyte mitochondrial genes and the forkhead factor FOXO2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone. <i>Diabetology and Metabolic Syndrome</i> , 2011 , 3, 32	5.6	19
39	Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. <i>PLoS ONE</i> , 2013 , 8, e62650	3.7	18
38	Predicting mortality in people with type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data. <i>Diabetic Medicine</i> , 2014 , 31, 954-62	3.5	17
37	Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. <i>Diabetes Therapy</i> , 2014 , 5, 591-607	3.6	17

36	LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes. <i>Diabetic Medicine</i> , 2016 , 33, 316-23	3.5	17
35	Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. <i>Diabetologia</i> , 2011 , 54, 2544-51	10.3	16
34	Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practice. <i>Diabetes Therapy</i> , 2014 , 5, 243-54	3.6	15
33	Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study. <i>Diabetes Therapy</i> , 2015 , 6, 635-642	3.6	15
32	Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men. <i>PLoS ONE</i> , 2016 , 11, e0145890	3.7	15
31	Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). <i>BMJ Open Diabetes Research and Care</i> , 2015 , 3, e000059	4.5	14
30	Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. <i>BMJ Open</i> , 2013 , 3,	3	14
29	Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population. <i>Journal of Diabetes and Its Complications</i> , 2013 , 27, 229-34	3.2	13
28	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2020 , 43, 3007-3015	14.6	13
27	Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register. <i>Diabetologia</i> , 2015 , 58, 1203-11	10.3	12
26	Amelioration of insulin resistance by rosiglitazone is associated with increased adipose cell size in obese type 2 diabetic patients. <i>Adipocyte</i> , 2014 , 3, 314-21	3.2	12
25	A method to predict the metabolic effects of changes in insulin treatment in subgroups of a large population based patient cohort. <i>European Journal of Epidemiology</i> , 2007 , 22, 151-7	12.1	12
24	Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels. <i>Diabetes Care</i> , 2016 , 39, e42-3	14.6	9
23	Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population--A prospective cohort study. <i>BMC Endocrine Disorders</i> , 2015 , 15, 51	3.3	9
22	Time trends in absolute and modifiable coronary heart disease risk in patients with Type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003-2008. <i>Diabetic Medicine</i> , 2012 , 29, 198-206	3.5	9
21	Predicting Changes in Cardiovascular Risk Factors in Type 2 Diabetes in the Post-UKPDS Era: Longitudinal Analysis of the Swedish National Diabetes Register. <i>Journal of Diabetes Research</i> , 2013 , 2013, 241347	3.9	8
20	The effect of insulin lispro on glycemic control in a large patient cohort. <i>Diabetes Technology and Therapeutics</i> , 2009 , 11, 51-6	8.1	8
19	Potential Benefits and Harms of Gastric Bypass Surgery in Obese Individuals With Type 1 Diabetes: A Nationwide, Matched, Observational Cohort Study. <i>Diabetes Care</i> , 2020 , 43, 3079-3085	14.6	8

18	Different methods to present the effect of blood pressure on cardiovascular diseases by Cox regression. <i>Journal of Hypertension</i> , 2012 , 30, 235-7	1.9	6
17	Cephalic phase of insulin secretion in response to a meal is unrelated to family history of type 2 diabetes. <i>PLoS ONE</i> , 2017 , 12, e0173654	3.7	6
16	Potential Effects of Bariatric Surgery on the Incidence of Heart Failure and Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Obesity and on Mortality in Patients With Preexisting Heart Failure: A Nationwide, Matched, Observational Cohort Study. <i>Journal of the American Heart Association</i> , 2021 , 10, e019323	6	6
15	Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey. <i>Diabetes Therapy</i> , 2019 , 10, 1523-1530	3.6	5
14	A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 1741-1749	14.6	5
13	The role of chloramines in treatment of diabetic foot ulcers: an exploratory multicentre randomised controlled trial. <i>Clinical Diabetes and Endocrinology</i> , 2016 , 2, 6	4.7	5
12	Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden. <i>Diabetes Therapy</i> , 2020 , 11, 1807-1820	3.6	4
11	Pathogenesis and treatment of diabetic vascular disease - illustrated by two cases. <i>Journal of Internal Medicine</i> , 2006 , 260, 409-20	10.8	4
10	Early Clinical Indicators of Addison Disease in Adults With Type 1 Diabetes: A Nationwide, Observational, Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 1148-1157	5.6	3
9	Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study. <i>Clinical Diabetes and Endocrinology</i> , 2017 , 3, 5	4.7	3
8	Development of a life expectancy table for individuals with type 1 diabetes. <i>Diabetologia</i> , 2021 , 64, 2228-2236	8.3	3
7	Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey. <i>Diabetes Therapy</i> , 2020 , 11, 725-734	3.6	2
6	Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.. <i>PharmacoEconomics - Open</i> , 2022 , 1	2.1	2
5	Population median imputation was noninferior to complex approaches for imputing missing values in cardiovascular prediction models in clinical practice.. <i>Journal of Clinical Epidemiology</i> , 2022 ,	5.7	2
4	Electrical atrial vulnerability and renal complications in type 2 diabetes. Reply to Montaigne D, Coisne A, Sosner P et al [letter]. <i>Diabetologia</i> , 2016 , 59, 863-4	10.3	1
3	Increased Urine IgM and IgG(2) Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes. <i>Biochemistry Research International</i> , 2012 , 2012, 480529	2.4	1
2	Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. <i>Diabetologia</i> , 2021 , 64, 2204-2214	10.3	1
1	Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice. <i>Clinical Diabetes and Endocrinology</i> , 2015 , 1, 17	4.7	

